We describe herein the clinical picture and treatment response to the JAK-inhibitor ruxolitinib in a 5-year-old girl affected by Aicardi-Goutières Syndrome type 6 (AGS6) due to <i>ADAR1</i> mutation. The gene discussed is ADAR; the disease is Aicardi-Goutieres syndrome 6.